Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.
You may also be interested in...
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
Abbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.